Literature DB >> 32043766

Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Hussein A Assi1, Sarbajit Mukherjee2, Pamela L Kunz3, Michael Machiorlatti4, Sara Vesely4, Vipul Pareek1, Hassan Hatoum1.   

Abstract

BACKGROUND: Pancreatic neuroendocrine tumors (panNETs) are a rare group of tumors that make up 2%-3% of pancreatic tumors. Recommended treatment for panNETs generally consists of resection for symptomatic or large asymptomatic tumors; however, optimal management for localized disease is still controversial, with conflicting recommendations in established guidelines. Our study aim is to compare surgical intervention versus active surveillance in nonmetastatic panNETs by size of primary tumor.
MATERIALS AND METHODS: Using the National Cancer Database, we identified 2,004 patients diagnosed with localized well-differentiated, nonfunctional panNETs (NF-panNETs) between 2004 and 2015. Patients' clinicopathologic characteristics, treatment modalities, and overall survival (OS) were analyzed using frequency statistics, chi-square, and Kaplan-Meier curves. The objective of the study is to assess the outcome of surgical resection versus nonoperative management in patients with panNETs with different tumor sizes.
RESULTS: Tumor sizes were divided into three categories: <1 cm, 1-2 cm, and >2 cm. The number of patients with tumor size <1 cm, 1-2 cm, and >2 cm was 220 (11%), 794 (39.6%), and 990 (49.4%), respectively. Overall, 1,781 underwent surgical resection, whereas 223 patients did not. Median follow-up was 25.9 months. After adjusting for covariates, surgical resection was associated with improved OS in patients with tumor size 1-2 cm (hazard ratio [HR] = 0.37) and >2c m (HR = 0.30) but not <1 cm (HR = 2.81). Independent prognostic factors were age at diagnosis, Charlson-Deyo comorbidity score, stage, tumor location, and surgical resection. Higher tumor grade was not associated with worse OS.
CONCLUSION: Our findings suggest that active surveillance is potentially a safe approach for NF-panNETs <1 cm. Larger tumors likely need active intervention. Intermediate-grade tumors did not result in worse survival outcome compared with low-grade tumors. Future studies might consider prospective randomized clinical trials to validate our findings. IMPLICATIONS FOR PRACTICE: The present study seeks to address the discrepancy in treatment recommendations in the management of nonfunctional pancreatic neuroendocrine tumors (NF-panNETs) by evaluating whether surgical resection is associated with improved overall survival in different tumor size groups as well as elucidating independent prognostic factors in patients with NF-panNETs. Data from the National Cancer Database were reviewed. This study's findings suggest that active surveillance is potentially a safe approach for NF-panNETs <1 cm. Larger tumors likely need active intervention. Independent prognostic factors include age at diagnosis, Charlson-Deyo comorbidity score, stage, tumor location, and surgical resection. These findings will help guide medical and surgical oncologists when formulating treatment plans for patients with small NF-panNETs. © AlphaMed Press 2019.

Entities:  

Keywords:  Database; Neuroendocrine tumors; Pancreas; Surgical oncology

Mesh:

Year:  2019        PMID: 32043766      PMCID: PMC7011621          DOI: 10.1634/theoncologist.2019-0466

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  28 in total

1.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Authors:  Massimo Falconi; Detlef Klaus Bartsch; Barbro Eriksson; Günter Klöppel; José M Lopes; Juan M O'Connor; Ramón Salazar; Babs G Taal; Marie Pierre Vullierme; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

3.  Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.

Authors:  Alex B Haynes; Vikram Deshpande; Thun Ingkakul; Parsia A Vagefi; Jackie Szymonifka; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Arch Surg       Date:  2011-05

Review 4.  The epidemiology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Anthony Chan; Bernhard Svejda; Mark Kidd; Irvin M Modlin
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

5.  Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Sébastien Gaujoux; Stefano Partelli; Frédérique Maire; Mirko D'Onofrio; Béatrice Larroque; Domenico Tamburrino; Alain Sauvanet; Massimo Falconi; Philippe Ruszniewski
Journal:  J Clin Endocrinol Metab       Date:  2013-09-20       Impact factor: 5.958

6.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

Authors:  Tetsuhide Ito; Hironobu Sasano; Masao Tanaka; R Yoshiyuki Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Kazuhiko Nakamura; Hisato Igarashi; Robert T Jensen; Bertram Wiedenmann; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

7.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

8.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.

Authors:  T R Halfdanarson; K G Rabe; J Rubin; G M Petersen
Journal:  Ann Oncol       Date:  2008-05-30       Impact factor: 32.976

9.  NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Authors:  Manisha H Shah; Whitney S Goldner; Thorvardur R Halfdanarson; Emily Bergsland; Jordan D Berlin; Daniel Halperin; Jennifer Chan; Matthew H Kulke; Al B Benson; Lawrence S Blaszkowsky; Jennifer Eads; Paul F Engstrom; Paul Fanta; Thomas Giordano; Jin He; Martin J Heslin; Gregory P Kalemkerian; Fouad Kandeel; Sajid A Khan; Wajih Zaheer Kidwai; Pamela L Kunz; Boris W Kuvshinoff; Christopher Lieu; Venu G Pillarisetty; Leonard Saltz; Julie Ann Sosa; Jonathan R Strosberg; Craig A Sussman; Nikolaos A Trikalinos; Nataliya A Uboha; Jonathan Whisenant; Terence Wong; James C Yao; Jennifer L Burns; Ndiya Ogba; Griselda Zuccarino-Catania
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 11.908

Review 10.  Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis.

Authors:  Panagiotis Drymousis; Dimitri A Raptis; Duncan Spalding; Laureano Fernandez-Cruz; Deepak Menon; Stefan Breitenstein; Brian Davidson; Andrea Frilling
Journal:  HPB (Oxford)       Date:  2013-11-07       Impact factor: 3.647

View more
  10 in total

1.  The Landmark Series: Pancreatic Neuroendocrine Tumors.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2020-09-18       Impact factor: 5.344

Review 2.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Authors:  Francesca Fermi; Valentina Andreasi; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Curr Oncol Rep       Date:  2022-01-25       Impact factor: 5.075

3.  It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.

Authors:  Patrick W Underwood; Andrea N Riner; Dan Neal; Miles E Cameron; Anastasiya Yakovenko; Sushanth Reddy; John Bart Rose; Steven J Hughes; Jose G Trevino
Journal:  J Surg Oncol       Date:  2021-09-09       Impact factor: 2.885

Review 4.  Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

Authors:  Pernille Holmager; Seppo W Langer; Andreas Kjaer; Lene Ringholm; Rajendra Singh Garbyal; Hans-Christian Pommergaard; Carsten Palnæs Hansen; Birgitte Federspiel; Mikkel Andreassen; Ulrich Knigge
Journal:  Curr Treat Options Oncol       Date:  2022-04-01

5.  Enucleation Is a Feasible Procedure for Well-Differentiated pNEN-A Matched Pair Analysis.

Authors:  Anna Nießen; Fabiola A Bechtiger; Ulf Hinz; Magdalena Lewosinska; Franck Billmann; Thilo Hackert; Markus W Büchler; Simon Schimmack
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

Review 6.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

7.  Risk of malignancy and prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors.

Authors:  Xi Liu; Wenjie Chin; Chenggeng Pan; Weichen Zhang; Jun Yu; Shusen Zheng; Yuanxing Liu
Journal:  Gland Surg       Date:  2021-01

8.  Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Juwan Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  World J Gastrointest Oncol       Date:  2020-10-15

9.  Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis.

Authors:  Tulan Hu; Wei Wang; Chiyi He
Journal:  J Oncol       Date:  2021-10-31       Impact factor: 4.375

10.  Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis.

Authors:  Martina T Mogl; Eva M Dobrindt; Josephine Buschermöhle; Claudia Bures; Johann Pratschke; Holger Amthauer; Christoph Wetz; Henning Jann
Journal:  Visc Med       Date:  2020-01-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.